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a b s t r a c t
The identiﬁcation of recent HIV infection is important for epidemiological studies and to
monitor the epidemic. The objective of this study was to evaluate two rapid tests that are
easily available to the Brazilian scientiﬁc community for using as markers of recent HIV
infection. The Rapid Test – HIV-1/2 Bio-Manguinhos (Bio-Manguinhos/Fiocruz, Brazil) and
the Rapid Check HIV 1&2 (NDI-UFES, Center for Infectious Diseases, Universidade Federal
do Espírito Santo) were tested, using 489 samples with HIV positive serology, from blood
donors, previously classiﬁed as recent or long-term infection by serological testing algorithm
for recent HIV seroconversion (STARHS) or LS-HIV Vitros assay methods. The samples were
diluted prior to testing (1:50 and 1:100 for the Rapid Test – HIV-1/2 Bio-Manguinhos, and 1:500
and 1:600 for the Rapid Check HIV 1&2). Negative samples were considered recent infection,
whereas those showing any color intensity were associated with long-term infection. The
best dilutions were 1:100 for HIV-1/2 Bio-Manguinhos test (Kappa = 0.840; overall agreement
= 0.93), and 1:500 for the Rapid Check HIV 1&2 (Kappa = 0.867; overall agreement = 0.94). The
results suggest that both rapid tests can be used to detect recent seroconversion.
© 2012 Elsevier Editora Ltda. All rights reserved.
Introduction
Despite the great progress achieved in preventing new human
immunodeﬁciency virus (HIV) infections and the reduction of
∗ Corresponding author at: Av. Dr. Enéas de Carvalho Aguiar, 470, 05403-000, São Paulo, SP, Brazil.
E-mail address: sabinoec@gmail.com (E.C. Sabino).
the annual number of acquired immunodeﬁciency syndrome
(AIDS)-related deaths, the number of people living with HIV
continues to grow worldwide. In 2010, 34 million people were
estimated to be infected globally, a number 17% higher than in
2001, and the prevalence was nearly three times higher than
1413-8670/$ – see front matter © 2012 Elsevier Editora Ltda. All rights reserved.
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that found in 1990. In the same period, there were 2.7 million
newcases,whichmeansover 7,000newHIV infectionsper day,
and 1.8 million annual deaths from AIDS.1 There is evidence
of success in HIV prevention in diverse settings, such as the
reduction on the annual rate of new HIV infections around the
globe, as well as a lower prevalence of HIV among young peo-
ple in several countries.2,3 Efforts to prevent HIV transmission
should focus on recent infections, due to their greater impact
on the spread of the epidemic.
The identiﬁcation of populations at risk of HIV infection is
a priority for public health and epidemiological surveillance.
In recent years, epidemiologists have used different laboratory
tests to estimate the incidence of HIV in certain populations,
or to check the number of new infections in a given period of
time.4–7 These strategies are important tools to identify popu-
lationswith high rates of ongoing transmission, to understand
the patterns of transmission, to monitor and direct resources
and prevention programs (especially in low-income countries,
where the concentration of cases is higher), and to assess the
future of the HIV epidemic.8–11
Likewise, for studies that identify subtypes of HIV-1 or
patterns of drug resistance in infected individuals, the identi-
ﬁcation of recent infected individuals can provide important
information about the dynamics of the epidemic.12–14
Detection of early infection can also be of clinical signiﬁ-
cance to the infected individual. The identiﬁcation of people
at an early stage of infection may accelerate the onset of
treatment, improving long-term prognosis. Early treatment,
along with appropriate counseling and partner notiﬁcation,
can help reduce secondary transmission by the newly infected
partners.15–17
The determination of incidence from conventional epi-
demiological methods is complex and expensive. The
development of tools that could indicatewhether apersonwas
infected recently has always been a priority for HIV research.
In 1998, Janssen et al.18 described the serological testing algo-
rithm for recent seroconversion (STARHS) to estimate the
incidence of HIV-1 in different populations. The technique
was based on the principle that antibody titers against HIV
increase gradually over the initial months after seroconver-
sion. Themethodwas based on enzyme immunoassays (ELISA
– enzyme-linked immunoabsorbent assay) of the ﬁrst gener-
ation (Abbott, and later manufactured by Organon Teknika).
Subsequently, studies have shown that this technology could
showunspeciﬁc recent infection results amongwith otherHIV
subtypes, since the test is based on HIV-1 subtypes B antigen.
Another problem is that the companies discontinued the ﬁrst
generation tests. In 2002, Parekh et al.19 developed a new IgG
capture enzyme immunoassay (BED-EIA), which is based on
the detection of gradual increase in the proportion of HIV-
speciﬁc IgG 1 and total IgG after seroconversion. This test
showed a similar sensitivity to detect speciﬁc antibodies to
the various HIV-1 subtypes. These methods can differentiate
individuals with recent seroconversion from long-term infec-
tion within about six months after seroconversion, and can
estimate HIV incidence using a single cross-sectional study.20
However, false positive results also occurred among long-
term infection. Factors such as heterogeneity of the immune
response to HIV-1 genotype and use of antiretroviral therapy
may cause misclassiﬁcation. Thus, these assays are used at a
population level, and should not be used as a diagnostic tool,
since theymay bemisleading for the individual case deﬁnition
of recent infection.
Another limiting factor for their use was the need for spe-
cial equipment to perform the immunoassays, and the many
hours required to obtain the results.21,22 In places with limited
resources, where the majority of diagnostic tests are per-
formed using HIV rapid tests, these disadvantages may be of
concern, and for those reasons, it is necessary to develop and
validate simple tests that can be used continuously, regardless
of any commercial source.21
The development of simple, rapid tests with high sensitiv-
ity and speciﬁcity was a major breakthrough in the diagnosis
of HIV infection. These tests provide results in a very short
time (minutes), do not require special laboratory equipment,
and are, in addition, very economical, having beenwidely used
as diagnostic methods, particularly in regions with limited
resources and high prevalence of HIV infection.23–25 The avail-
ability of a rapid test that also has the ability to accurately
determine the incidence would be a useful epidemiological
tool to assess the HIV epidemic in these regions.25,26
Recently, some researchers8,27,28 evaluated the use of rapid
tests for the diagnosis of recent infection. The aim of the
present study was to evaluate rapid tests manufactured in
Brazil for this purpose.
Materials and methods
Two HIV rapid tests (RT) were analyzed: Rapid Test - HIV-1/2
Bio-Manguinhos (Bio-Manguinhos/Fiocruz, Brazil) and Rapid
Check HIV 1&2 (NDI-UFES, Center for Infectious Diseases, Uni-
versidade Federal do Espírito Santo). Both tests are provided
solely by the Ministry of Health, and are not commercialized.
These assays consist of speciﬁc HIV-1/2 antigens adsorbed on
special membranes. The results can be visualized in the form
of bands on the membranes. For the purposes of the present
research, theoriginal assaysweremodiﬁedexclusively bydilu-
tion of samples, and the reagents and materials were not
changed.
A total of 489 HIV-positive serum samples from the Epi-
demiology Recipient and Donor Evaluation Study (REDS)29
were used for this evaluation. Of these, 147, 155, and 187 were
fromblooddonations of the years 2007, 2008, and 2009, respec-
tively. Samples from 2007 had previously been evaluated by
the STARHS method (Vironostika HIV-1 microElisa System;
bioMérieux – Raleigh, NC, USA), while in the 2008 and 2009
samples, the LS-HIV Vitros Assay method (Ortho Diagnostics,
Raritan, NJ) was utilized.30 The results obtained during the
REDS were used to classify the samples as a recent or long-
term infection.
First, four samples classiﬁed as recent infection and four
samples classiﬁed as long-term infection were selected to
onset of standardization. Serial dilutions were made from 1:10
to 1:10,000 in negative human serum. From this preliminary
test, the best two dilutions were selected to evaluate a large
number of samples. Since these are tests whose results are
obtained by colorimetric bands, the reading was visual, on a
properly lit and ﬂat surface. Non-reactive samples after dilu-
tion, that is, with no band at the location indicated by the
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Table 1 – Comparison of different rapid test dilutions and the reference ELISA tests (STAHRS and LS-HIV).
Reference ELISA
Long-term Recent Total
HIV 1/2 Bio-Manguinhos
1:50
Long-term 330 (96.2%) 13 (3.8%) 343
Recent 35 (24%) 111 (76%) 146
1:100
Long-term 324 (94.5%) 19 (5.5%) 343
Recent 14 (9.6%) 132 (90.4%) 146
Rapid Check HIV 1 & 2
1:500
Long-term 327 (95.9%) 14 (4.1%) 341
Recent 13 (9%) 132 (91%) 145
1:600
Long-term 316 (92.7%) 25 (7.3%) 341
Recent 7 (4.8%) 138 (95.2%) 145
HIV-1/2 Bio-Manguinhos 1:50 – Kappa coefﬁcient = 0.755; Overall agreement = 0.90.
HIV-1/2 Bio-Manguinhos 1:100 – Kappa coefﬁcient = 0.840; Overall agreement = 0.93.
Rapid Check HIV 1&2 1:500 – Kappa coefﬁcient = 0.867; Overall agreement = 0.94.
Rapid Check HIV 1&2 1:600 – Kappa coefﬁcient = 0.848; Overall agreement = 0.93.
colorimetric test, were associated with cases of recent infec-
tion; those that had any staining intensity at the location
indicated were associated with long-term infections.
For the Rapid Test - HIV-1/2 Bio-Manguinhos, the 1:50 and
1:100 dilutions were evaluated, as both had similar results to
the samples tested. Samples were diluted in plasma and 5L
of the ﬁnal dilution was used for testing.
For the Rapid CheckHIV 1&2 assay, the 1:500 and 1:600 dilu-
tions were used. Samples were diluted in negative plasma and
10L were used for testing.
Apart from the dilutions, the tests were performed accord-
ing to the manufacturer’s instructions.
Statistical analysis was performed using the kappa coef-
ﬁcient, which assesses the agreement beyond chance of the
results with the reference methods (STARHS and LS-HIV Vit-
ros assay). The sensitivity and speciﬁcity of each assay were
determined with a conﬁdence interval of 95%.
Results
Table 1 shows the test results obtained by the HIV-1/2 Bio-
Manguinhos using the best two dilutions (1:50 and 1:100), and
the tests results by the Rapid Check HIV 1&2 at dilutions 1:500
and 1:600. Of the 146 samples deﬁned as recent infection by
reference ELISA, 111 (76%) and 132 (90.4%) were considered
to be new infection by HIV-1/2 Bio-Manguinhos at dilutions
of 1:50 and 1:100, respectively. Of the 343 long-term infection
samples, 330 (96.2%) and 324 (94.5%) were considered to be
long-term by the HIV-1/2 Bio-Manguinhos in 1:50 and 1:100
dilutions, respectively. Therefore, the 1:100 dilution was cho-
sen for this test. For the test Rapid Check HIV 1&2, of 145
samples deﬁned as recent infection by reference ELISAs, 132
(91%) were considered recent infection at a dilution of 1:500,
and 138 (95.2%) at a dilution of 1:600. Of the 341 samples
deﬁned as long-term, Rapid Check detected 327 (95.9%) when
at a dilution of 1:500, and 316 (92.7%) at a dilution of 1:600.
Table 2 summarizes the results obtained by comparing
each test with each reference ELISA. The overall concordance
was similar, ranging from 0.90 to 0.95.
Discussion
RTs are a practical and economical method for the diagno-
sis of recent HIV infection. Especially in places with limited
Table 2 – Comparison of sensitivity, speciﬁcity, kappa coefﬁcient, overall agreement, positive predictive value (PPV), and
negative predictive value (NPV) of tests at their best dilutions.
Parameters (95%CI) Bio-Manguinhos x STARHS
n = 147
Bio-Manguinhos x LS-HIV
n = 342
Rapid Check x
STARHS*n = 145
Rapid Check x LS-HIV
n = 341
Sensitivity 0.9889 (0.9396-0.9997) 0.8972 (0.8531-0.9318) 0.9775 (0.9212-0.9973) 0.9524 (0.9183-0.9752)
Speciﬁcity 0.8772 (0.7632-0.9492) 0.9213 (0.8446-0.9678) 0.8571 (0.7378-0.9362) 0.9438 (0.8737-0.9815)
Kappa coefﬁcient 0.8831 (0.8047-0.9616) 0.7656 (0.6906-0.8407) 0.8516 (0.7632-0.9399) 0.8740 (0.8157-0.9322)
Overall agreement 0.9456 (0.8956-0.9762) 0.9035 (0.8672-0.9326) 0.9310 (0.8768-0.9664) 0.9501 (0.9214-0.9707)
PPV 0.9671 (0.8555-0.9702) 0.9701 (0.9393-0.9879) 0.9158 (0.8408-0.9629) 0.9796 (0.9530-0.9933)
NVP 0.9804 (0.8955-0.9995) 0.7593 (0.6675-0.8363) 0.9600 (0.8629-0.9951) 0.8750 (0.7918-0.9337)
Rapid test HIV-1/2 Bio-Manguinhos in 1:100 dilution; Rapid Check HIV 1 & 2 in 1:500 dilution.
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resources, to estimate HIV incidence, using an RT could be an
important tool for guiding prevention programs, identifying
populations with high transmission rates, as well as under-
standing the patterns of transmission.
Incidence calculation by prospective cohort studies is
expensive, and generally the samples are non-representative
of the general population. Mathematical models created for
these estimations are based on epidemiological data on HIV
prevalence, diagnosis of AIDS, or death rates. However, they
are difﬁcult to standardize or require complex statistical
methods.6 Because of this complexity and the limitations of
methods to estimate HIV incidence, different laboratory tech-
niques have been developed, seeking to distinguish recent
infections from long-term infections.7,11,18,19,21,27,28,31–44 These
tests, however, depend on the calibration panels, which
are not always available in a given country. In the cur-
rent study, techniques that are easily accessed by the
Brazilian scientiﬁc community and public services were
evaluated in order to facilitate the development of epi-
demiological studies needed to detect incident cases of HIV
infection.
The results suggest that, by modifying the sample dilution,
HIV-1/2 RTs had a similar performance as the reference ELISAs
(STARHS and LS-HIV Vitros assay) to discriminate between
recent and long-term infection.
The overall agreement between the RTs and the refer-
ence tests was 93% on average. As these tests are visually
interpreted, it was not possible to calculate the coefﬁcient of
variation.
In 2005, Soroka et al.28 modiﬁed three protocols for
the detection of recent seroconversion by RT. Determine
HIV-1/2 (Abbott Laboratories), OraQuick Advance HIV-1/2
(OraSure Technologies), and SeroStrip HIV-1/2 (Chem-Bio)
were used, and obtained a general agreement of 95% for
the tested samples. More recently, Kshatriya et al.27 also
compared Determine HIV-1/2 and OraQuick Advance HIV-
1/2 tests, and showed an agreement of 97% and 93%,
respectively.
The samples used in the present study were previously
tested by the reference methods STARHS and LS-HIV Vit-
ros assay.29 Similar results were observed with both assays.
However, in 2011, Kassanjee45 suggested caution in the
use of LS-HIV Vitros Assay, since it has high false-recent
rates.
Unfortunately, the results of both tests were not available
for the same sample, thus it was not possible to determine the
agreement between the two tests in the tested samples. In this
sense, the limitation of this study is the same as reported by
themajority of other investigators seeking to standardize tests
for this purpose, that is, the lack of availability of speciﬁc sam-
ples in anadequate volume thatwouldallow for the evaluation
of a test series, comparing performance among them.
Another limitation of this study is that the interval between
infection and seroconversion could not be determined. The
STARHS and LS-HIV Vitros assay tests were standardized
for a window period of 170 days using samples with the
window period previously known. The fact that this study’s
methodology has shown good correlation with these meth-
ods does not necessarily imply that the window period is the
same.
Conclusion
It is still premature to use this technology to deﬁne incidence.
However, it could be used to screen recently infected individ-
uals, who would need to be conﬁrmed by a follow up-sample,
or to be used in studies comparing the relative rate of newly
infected individuals in different populations.
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